MedTrace Logo

Aspirin for the Prevention of Recurrent Venous Thromboembolism

NCT00222677 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2011-08-23

No results posted yet for this study

Summary

To determine whether aspirin is more effective than placebo for the prevention of recurrent symptomatic venous thromboembolism when given for at least two years after the initial 6-12 month of oral anticoagulant therapy in patients with idiopathic venous thromboembolism

Conditions

Interventions

DRUG

aspirin

100 mg daily

Sponsors & Collaborators

  • University Of Perugia

    lead OTHER

Principal Investigators

  • Giancarlo Agnelli, MD · Department of Internal Medicine - University of Perugia

  • Cecilia Becattini, MD · Department of Internal Medicine - University of Perugia

  • Paolo Prandoni, PhD · University of Padova

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-05-31
Primary Completion
2012-01-31

Countries

  • Austria
  • Italy

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00222677 on ClinicalTrials.gov